STUDY PROTOCOL

Association between sarcopenia and osteoarthritis: A protocol for meta-analysis

Haochen Wang*, Ning Wang*, Yilun Wang, Hui Li

Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China

* These authors contributed equally to this work.
* lihui1988@csu.edu.cn

Abstract

Background

Sarcopenia, a relatively new syndrome referring to the age-related decline of muscle strength and degenerative loss of skeletal muscle mass and function, often resulting in frailty, disability, and mortality. Osteoarthritis, as a prevalent joint degenerative disease, is affecting over 250 million patients worldwide, and it is the fifth leading cause of disability. Despite the high prevalence of osteoarthritis, there are still lack of efficient treatment potions in clinics, partially due to the heterogeneous and complexity of osteoarthritis pathology. Previous studies revealed the association between sarcopenia and osteoarthritis, but the conclusions remain controversial and the prevalence of sarcopenia within osteoarthritis patients still needs to be elucidated. To identify the current evidence on the prevalence of sarcopenia and its association with osteoarthritis across studies, we performed this systematic review and meta-analysis that would help us to further confirm the association between these two diseases.

Methods and analysis

Electronic sources including PubMed, Embase, and Web of Science will be searched systematically following appropriate strategies to identify relevant studies from inception up to 28 February 2022 with no language restriction. Two investigators will evaluate the preselected studies independently for inclusion, data extraction and quality assessment using a standardized protocol. Meta-analysis will be performed to pool the estimated effect using studies assessing an association between sarcopenia and osteoarthritis. Subgroup analyses will also be performed when data are sufficient. Heterogeneity and publication bias of included studies will be investigated.

PROSPERO registration number

CRD42020155694.
Introduction

With global population aging and increased longevity, aging and age-related diseases have become substantial burden and inevitable challenges worldwide. Sarcopenia, defined as an age-related muscle mass decline and muscle strength loss, results in reduced mobility, function and quality of life, and thus greatly increasing healthcare expenditures [1]. Although sarcopenia is a relatively new syndrome which was first described in the 1980s [2], it has become a common condition with an estimated prevalence from 12.9% to 40.4% with various diagnostic criteria [3, 4]. Sarcopenia is not only simply recognized as an age-related syndrome but also found to be correlated with increased risk of fall/fracture [5, 6], functional decline [7], multiple chronic diseases [8–10], loss of independence [11–13], frailty and mortality [14]. Sarcopenia is becoming a critical public health burden compounded by an expanding elderly population, being reported that the direct cost for medical spending due to sarcopenia was around $18.5 billion (i.e., 1.5% of the total health care spending) [15] for the year of 2000 in the United States, and since then, the economic burden of this progressive and generalized skeletal muscular disorder has grown substantially [16].

Osteoarthritis, the most common degenerative joint disease, is a leading contributor of physical disability nowadays [17, 18]. Since osteoarthritis has brought a severe impact on both individuals and the society as a whole, a comprehensive understanding of the underlying mechanism and potential risk factors of osteoarthritis has a significant importance [19]. Multiple types of risk factors have been identified to be correlated with pathogenesis of osteoarthritis [20], among which muscle weakness is considered as one of the major ones [21, 22]. For the various recommended intervention measures of osteoarthritis, functional exercise and muscle strength exercise have been drawing growing attention. Previous studies have suggested that there appears to be a bidirectional relationship between muscle weakness and osteoarthritis, muscle weakness might be a contributor to osteoarthritis progression and vice versa. On the one hand, as the atrophy or weakness of periarticular muscles would lead to the development, progression and severity of osteoarthritis, patients with osteoarthritis would adapt their lifestyle to sedentary and inactivity to avoid joint pain and stiffness [23–26]. Subsequently, sedentary and physical inactivity would in turn reduces energy expenditure and results in muscle wasting, thus would lower the joint-protective ability [27]. On the other hand, pain and stiffness of osteoarthritis joints cause physical inactivity, which would lead to adipose tissue gains and overweight development in these patients. The pressure of increased load further exacerbates the progression of osteoarthritis, and it is the combination of these factors that is considered to create and perpetuate a vicious cycle between muscle weakness and osteoarthritis [28, 29].

Yet, few studies considered muscle weakness or atrophy as a disease (i.e., sarcopenia) and the relationship between sarcopenia and osteoarthritis has remained ambiguous and no strong consensus has been reached [30]. Some suggested that sarcopenia was likely to positively correlate with osteoarthritis [31–34], and other studies did not support this observation [35, 36]. One of the plausible reason could be the definition of sarcopenia has been progressing and updating for decades, but full agreement on the involved variables and cutoff points has not reached yet [3], and this may lead to different prevalence rates. Furthermore, different anatomical location of osteoarthritis may exhibit different associations with sarcopenia. One study found that sarcopenia was associated with osteoarthritis at the hip and lower limbs [34], while another study reported that sarcopenia was independently associated with knee osteoarthritis and inversely associated with lumbar spine osteoarthritis [33]. One approach to synthesis existing knowledge is to identify consistencies across studies through a meta-analysis, but to our knowledge, no such study has systematically reviewed current evidence on the association between sarcopenia and osteoarthritis.
Therefore, this meta-analysis study aims to identify the association between sarcopenia and osteoarthritis more comprehensively. The results of this study will further our knowledge on whether sarcopenia and osteoarthritis are associated at different targeted joints, thereby enabling the development of preventive and therapeutic strategies for both sarcopenia and osteoarthritis.

**Methods**

**Study design**

This meta-analysis protocol has been registered with the international prospective register of systematic reviews PROSPERO network (registration number: CRD42020155694). The consent of this protocol is developed based on the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) 2015 Statement Guidelines (S1 Appendix) [37].

**Eligibility criteria**

The initially-retrieved studies will be evaluated for inclusion according to the following inclusion criteria: (1) observational studies including cohort studies, cross-sectional studies or case-control studies that focus on the prevalence of sarcopenia in patients with and without osteoarthritis, (2) diagnosis of sarcopenia using any definition criteria (e.g., low appendicular muscle mass criteria, or the European Working Group on Sarcopenia in Older People [EWGSOP] criteria including low handgrip strength and/or low walking speed in combination with low muscle mass), and (3) the age of included subjects are $\geq 60$ years. Studies will be excluded if they are: (1) lack of reporting on study outcomes and (2) duplicate publications.

**Information sources**

Three electronic databases (i.e., PubMed, Web of Science, and Embase) will be searched with appropriate search strategies from inception up to February 2022 from each platform or database. In addition, reference lists of the included literature and relevant systematic reviews will also be browsed to identify the eligible studies.

**Search strategy**

The search will be carried out by combining keywords terms or medical subject heading terms (MESH) for eligible studies from the databases mentioned above. The same search terms will be adapted based on the specific requirements of different syntax rules. The electronic search strategy is listed in Tables 1–3.

**Study selection**

Two investigators will screen the title and abstract of each retrieved study independently to identify eligible studies after removing duplicates. Full text will be reviewed according to the inclusion and exclusion criteria if the eligibility of studies is uncertain. Discussion will be made by consulting a third investigator for any disagreements between the two investigators. Studies will not be restricted on the language and publication date. Study selection will be documented and summarized based on the PRISMA flow diagram.

**Data extraction**

After systematic literature search is carried out, two investigators will screen the included studies independently and extract the following data from in a standardized format: name of
the author(s), year of publication, study design, setting of the study, data sources, study period, sample size, age range of the participants, sex distribution, prevalence of sarcopenia in patients with and without osteoarthritis. The effect sizes (i.e., odds ratio [OR], relative risk [RR] or hazard ratio [HR]) will be directly extracted or calculated on the basis of the relevant data in the original study as far as possible. If any data of interest is not available, we will contact the author(s) of the concerned study to obtain the supplemental data to the best extent. Any disagreements in data extraction will be consulting a third investigator to reach a consensus.

### Quality assessment

Two investigators will evaluated the quality of included studies independently according to the Newcastle-Ottawa Quality Scale (NOS) [38]. The NOS scale is a validated scale for non-randomized studies in meta-analysis that evaluates the risk of bias with broad perspectives: (1) the selection of the study groups; (2) the comparability of the groups; and (3) the ascertainment of

---

Table 1. Draft of search strategy to be used using PubMed electronic database.

| Number | Search terms |
|--------|--------------|
| 1      | "osteoarthritis"[Mesh] |
| 2      | osteoarthritis[Title/Abstract] |
| 3      | osteoarthro[Title/Abstract] |
| 4      | gonarthritis[Title/Abstract] |
| 5      | coxarthritis[Title/Abstract] |
| 6      | coxarthro[Title/Abstract] |
| 7      | osteoarthritis[Title/Abstract] |
| 8      | gonarthro[Title/Abstract] |
| 9      | OR/1-8 |
| 10     | "sarcopenia"[Mesh] |
| 11     | "muscle weakness"[Mesh] |
| 12     | sarcopen[Title/Abstract] |
| 13     | "muscle mass"[Title/Abstract] |
| 14     | "muscle volume"[Title/Abstract] |
| 15     | "muscle quality"[Title/Abstract] |
| 16     | "muscle size"[Title/Abstract] |
| 17     | "lean mass"[Title/Abstract] |
| 18     | "muscle strength"[Title/Abstract] |
| 19     | "grip strength"[Title/Abstract] |
| 20     | "gripping strength"[Title/Abstract] |
| 21     | "hand strength"[Title/Abstract] |
| 22     | "holding power"[Title/Abstract] |
| 23     | "grip dynamometer"[Title/Abstract] |
| 24     | handgrip[Title/Abstract] |
| 25     | "muscular atrophy"[Title/Abstract] |
| 26     | "muscle atrophy"[Title/Abstract] |
| 27     | "muscular dystrophy"[Title/Abstract] |
| 28     | "muscle dystrophy"[Title/Abstract] |
| 29     | "physical function"[Title/Abstract] |
| 30     | "muscle weakness"[Title/Abstract] |
| 31     | OR/10-30 |
| 32     | 9 AND 31 |

https://doi.org/10.1371/journal.pone.0272284.t001
either the exposure or outcome of interest for case-control or prospective/ retrospective cohort studies, respectively [39]. For the cross-sectional studies, an adapted form of NOS will be used to evaluates the risk of bias [40, 41]. Studies with more than five stars will be considered as high methodological quality. In case of any discrepancies, a consensus will be reached through

Table 2. Draft of search strategy to be used using Embase electronic database.

| Number | Search terms |
|--------|--------------|
| 1 | 'osteoarthritis'/exp |
| 2 | osteoarthritis:ti,ab,kw |
| 3 | osteoarthro:ti,ab,kw |
| 4 | gonarthritis:ti,ab,kw |
| 5 | gonarthro:ti,ab,kw |
| 6 | coxarthritis:ti,ab,kw |
| 7 | coxarthro:ti,ab,kw |
| 8 | osteoarthritis:ti,ab,kw |
| 9 | OR/1-8 |
| 10 | 'sarcopenia'/exp |
| 11 | 'muscle weakness'/exp |
| 12 | sarcopen:ti,ab,kw |
| 13 | 'muscle mass':ti,ab,kw |
| 14 | 'muscle volume':ti,ab,kw |
| 15 | 'muscle quality':ti,ab,kw |
| 16 | 'muscle size':ti,ab,kw |
| 17 | 'lean mass':ti,ab,kw |
| 18 | 'muscle strength':ti,ab,kw |
| 19 | 'grip strength':ti,ab,kw |
| 20 | 'gripping strength':ti,ab,kw |
| 21 | 'hand strength':ti,ab,kw |
| 22 | 'holding power':ti,ab,kw |
| 23 | 'grip dynamometer':ti,ab,kw |
| 24 | handgrip:ti,ab,kw |
| 25 | 'muscular atrophy':ti,ab,kw |
| 26 | 'muscle atrophy':ti,ab,kw |
| 27 | 'muscular dystrophy':ti,ab,kw |
| 28 | 'muscle dystrophy':ti,ab,kw |
| 29 | 'physical function':ti,ab,kw |
| 30 | 'muscle weakness':ti,ab,kw |
| 31 | OR/10-30 |
| 32 | 9 AND 31 |

https://doi.org/10.1371/journal.pone.0272284.t002

either the exposure or outcome of interest for case-control or prospective/ retrospective cohort studies, respectively [39]. For the cross-sectional studies, an adapted form of NOS will be used to evaluates the risk of bias [40, 41]. Studies with more than five stars will be considered as high methodological quality. In case of any discrepancies, a consensus will be reached through

Table 3. Draft of search strategy to be used using Web of Science electronic database.

| Number | Search terms |
|--------|--------------|
| 1 | TS = (osteoarthritis OR osteoarthro OR gonarthritis OR gonarthro OR coxarthritis OR coxarthro OR osteoarthritis) |
| 2 | TS = (sarcopen OR "muscle weakness" OR "muscle atrophy" OR "muscle mass" OR "muscle volume" OR "muscle quality" OR "muscle size" OR "lean mass" OR "muscle strength" OR "grip strength" OR "gripping strength" OR "hand strength" OR "holding power" OR "grip dynamometer" OR handgrip OR "muscular atrophy" OR "muscular dystrophy" OR "muscle dystrophy" OR "physical function" OR "muscle weakness") |
| 3 | 1 AND 2 |

https://doi.org/10.1371/journal.pone.0272284.t003
a discussion, with the assistance of a third reviewer when necessary. Studies with a high risk of bias (e.g., small-sample or low-quality studies) will be excluded and the reasons for their exclusion will be noted.

**Data analysis**

All data will be statistical analyzed using the statistical software Review Manager 5.3 software. The study characteristics will be summarized in narrative texts and baseline tables. Specifically, effect sizes (the pooled OR, RR or HR) and corresponding 95% CIs will be calculated respectively. Statistical heterogeneity between the studies will be evaluated with I² values, for highly heterogeneous studies (>50%) a random-effects model will be used. A fixed-effects model will be applied to perform data pooling when the level of heterogeneity is not significant. The meta-analysis is set to a statistical significance as p value < 0.05. When data are sufficient, this study will also perform subgroup analyses stratified by obesity (obesity and non-obesity) and different joints (hip, knee and hand).

**Assessment of publication bias**

The publication bias among various studies will be assessed using the visual examination of funnel plot and Egger’s test if ten or more studies are available. Asymmetric funnel plot may imply possible publication bias, small-study effects, or other factors. If asymmetry is caused by small-study effects, we will conduct sensitivity analysis by excluding these studies to explore how this affects the results and conclusions of the meta-analysis.

**Sensitivity analysis**

Sensitivity analysis will be performed to test the robustness of pooled results regarding study characteristics and methodological quality by removing some of the small-sample or low-quality studies. If heterogeneity exists, sensitivity analysis will be re-run while removing poor quality data in a step-by-step wise.

**Discussion**

As sarcopenia is a relatively new disorder with high incidence and prevalence in elderly population, it has seriously affected the health of the elderly throughout the world. It has been postulated that sarcopenia and osteoarthritis may be co-existing conditions [42]. But the pathophysiological mechanisms associated with sarcopenia and osteoarthritis are unclear. Plausible factors might include ageing, disuse and inflammation. Yet, the relevance of these findings has not been established. To explore the relationship between these two prevailing diseases, it is of great significance to conduct a meta-analysis to determine the impact of sarcopenia on osteoarthritis.

So far, there have been several studies on the correlation between sarcopenia and osteoarthritis. Of them, four studies suggested that sarcopenia was likely to positively correlate with osteoarthritis [31–34], and two studies showed that obesity and sarcopenic obesity, but not sarcopenia, were associated with osteoarthritis [35, 36]. In addition, one study found that sarcopenia was associated with osteoarthritis at the hip and lower limbs [34], while another study reported that sarcopenia was independently associated with knee osteoarthritis and inversely associated with lumbar spine osteoarthritis [33]. However, due to the variation in diagnostic criteria and classification of sarcopenia, the association between sarcopenia and osteoarthritis is still inconclusive [32, 35]. Previous studies analyzed sarcopenia by adopting different diagnosis standards and in relation to different weight-bearing joints osteoarthritis, which could be a possible reason why the literature findings were inconsistent. An earlier cross-sectional study
discussed the associations between low skeletal muscle mass and radiographic osteoarthritis of the hip, lumbar and knee joints, and the results showed that the skeletal muscle mass exhibited different associations with different joints [33]. Sarcopenia, as a disease affecting the whole body, may not only influence the knee joints but also other joints. According to the diagnostic criteria given by EWGSOP [1], sarcopenia can be diagnosed by the tests of muscle strength (usually based on grip strength), muscle mass (usually based on dual-energy X-ray absorptiometry or bioelectrical impedance analysis) and muscle function (usually based on gait speed, short physical performance battery, or time-up-and-go tests), which involve multiple joints of the body including hand, hip, and knee.

Nevertheless, sarcopenia, as well as sarcopenic obesity, have both been recognized as leading contributors of increased disability and mortality [14, 43]. Given that the effect of obesity towards osteoarthritis in previous studies, we will further perform subgroup and sensitivity analyses focusing on obesity or sarcopenic obesity as well. Previously, obesity, which is often represented by an increased body mass index (BMI) or body weight, was generally considered as a major risk factor of osteoarthritis [44]. However, in view of that the ratio of muscle mass over fat mass is changing constantly with the aging process [45–47], conventional anthropometric indicators, such as BMI and weight, may not be able to fully represent adiposity [48]. Recently, sarcopenia and sarcopenic obesity have been reported to be associated with a number of diseases including osteoarthritis [10, 29, 49]. Thus, subgroup and sensitivity analyses of sarcopenia, sarcopenic obesity and obesity will be conducted to better illustrate the relationship of these disorders.

The outcome of this meta-analysis may address an association between sarcopenia and osteoarthritis that is of pivotal importance to understanding the underlying mechanisms. The results from this study are also likely to inform healthcare a better decision-making treatment decision and to maximize the benefits of prevent and control osteoarthritis progression for limiting sarcopenia risk.

Supporting information
S1 Appendix.
(DOCX)

Acknowledgments
Everyone who contributed significantly to the work has been listed.

Author Contributions
Conceptualization: Haochen Wang, Yilun Wang.
Data curation: Haochen Wang.
Formal analysis: Ning Wang.
Methodology: Haochen Wang.
Writing – original draft: Haochen Wang, Ning Wang.
Writing – review & editing: Yilun Wang, Hui Li.

References
1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1):16–31. https://doi.org/10.1093/ageing/afy169 PMID: 30912372
2. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997; 127(5 Suppl):990S–1S. https://doi.org/10.1093/jn/127.5.990S PMID: 9164280

3. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019; 393(10191):2636–46. https://doi.org/10.1016/S0140-6736(19)31138-9 PMID: 31171417

4. Mayhew AJ, Amog K, Phillips S, Parise G, McNicholas PD, de Souza RJ, et al. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and meta-analyses. Age Ageing. 2019; 48(1):48–56. https://doi.org/10.1093/ageing/afy106 PMID: 30052707

5. Bischoff-Ferrari HA, Orav JE, Kanis JA, Rizzoli R, Schlogl M, Staehelin HB, et al. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporos Int. 2015; 26(12):2793–802. https://doi.org/10.1007/s00198-015-3194-y PMID: 26068298

6. Schaap LA, van Schoor NM, Lips P, Visser M. Associations of Sarcopenia Definitions, and Their Components, With the Incidence of Recurrent Falling and Fractures: The Longitudinal Aging Study Amsterdam. J Gerontol A Biol Sci Med Sci. 2018; 73(9):1196 e7–e15. https://doi.org/10.1093/gerona/gfy245 PMID: 29300839

7. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016; 7(1):28–36. https://doi.org/10.1002/jcsm.12048 PMID: 27066316

8. Bahat G, Ilhan B. Sarcopenia and the cardiometabolic syndrome: a narrative review. Eur Geriatr Med. 2016; 6:220–23. https://doi.org/10.1016/j.eurger.2015.12.012

9. Bone AE, Heppul N, Kon S, Maddocks M. Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis. 2017; 14(1):85–99. https://doi.org/10.1177/1479972316679664 PMID: 27923981

10. Chang KV, Hsu TH, Wu WT, Huang KC, Han DS. Association Between Sarcopenia and Cognitive Impairment: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2016; 17(12):1164 e7–e15. https://doi.org/10.1016/j.jamda.2016.09.013 PMID: 27816848

11. Dos Santos L, Cyrino ES, Antunes M, Santos DA, Sardinha LB. Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle. 2017; 8(2):245–50. https://doi.org/10.1002/jcsm.12160 PMID: 27897417

12. Akune T, Muraki S, Oka H, Tanaka S, Kawaguchi H, Tokimura F, et al. Incidence of certified need of care in the long-term care insurance system and its risk factors in the elderly of Japanese population-based cohorts: the ROAD study. Geriatr Gerontol Int. 2014; 14(3):695–701. Epub 2013/09/12. https://doi.org/10.1111/ggi.12155 PMID: 24020635

13. Steffl M, Bohannon RW, Sontakova L, Tufano J, Shiells K, Holmerova I. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017; 12:835–45. https://doi.org/10.2147/CIA.S132940 PMID: 28553092

14. De Buyser SL, Petrovic M, Taes YE, Toye KR, Kaufman JM, Lapauw B, et al. Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing. 2016; 45(5):602–8. https://doi.org/10.1093/ageing/afw071 PMID: 27126327

15. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. Osteoarthritis. Lancet. 2015; 386(9991):376–87. https://doi.org/10.1016/S0140-6736(14)60820-3 PMID: 25748615
22. Oiestad BE, Juhl CB, Eitzen I, Thorlund JB. Knee extensor muscle weakness is a risk factor for development of knee osteoarthritis. A systematic review and meta-analysis. Osteoarthritis Cartilage. 2015; 23 (2):171–7. Epub 2014/12/10. https://doi.org/10.1016/j.joca.2014.10.008 PMID: 25450853

23. Beattie KA, MacIntyre NJ, Ramadan K, Inglis D, Maly MR. Longitudinal changes in intermuscular fat volume and quadriceps muscle volume in the thighs of women with knee osteoarthritis. Arthritis Care Res (Hoboken). 2012; 64(1):22–9. https://doi.org/10.1002/acr.20628 PMID: 21905259

24. Loureiro A, Constantinoiu M, Diamond LE, Bebbington P, Barrett R. Individuals with mild-to-moderate hip osteoarthritis have lower limb muscle strength and volume deficits. BMC Musculoskelet Disord. 2018; 19 (1):303. Epub 2018/08/23. https://doi.org/10.1186/s12891-018-2230-4 PMID: 30131064

25. Dell’isola A, Wirth W, Steultjens M, Eckstein F, Culvenor AG. Knee extensor muscle weakness and radiographic knee osteoarthritis progression. Acta Orthop. 2018; 89(4):406–11. Epub 2018/05/02. https://doi.org/10.1080/17453674.2018.1464314 PMID: 29714070

26. Baker KR, Xu L, Zhang Y, Nevitt M, Liu J, Aliabadi P, et al. Quadriceps weakness is a risk factor for development of knee osteoarthritis: a population-based study. Int J Rheum Dis. 2019; 22(7):2447–57. Epub 2019/01/09. https://doi.org/10.1111/ijrd.13423 PMID: 30617856

27. Karlsson MK, Magnusson H, Coster M, Karlsson C, Rosengren BE. Patients with knee osteoarthritis have a phenotype with higher bone mass, higher fat mass, and lower lean body mass. Clin Orthop Relat Res. 2015; 473(1):258–64. Epub 20141004. https://doi.org/10.1007/s11999-014-3973-3 PMID: 25280553

28. Chung SM, Hyun MH, Lee E, Seo HS. Novel effects of sarcopenic osteoarthritis on metabolic syndrome, insulin resistance, osteoporosis, and bone fracture: the national survey. Osteoporos Int. 2016; 27(8):2447–57. Epub 2016/05/15. https://doi.org/10.1007/s00198-016-3854-0 PMID: 27177746

29. Godziuk K, Prado CM, Woodhouse LJ, Forhan M. The impact of sarcopenic obesity on knee and hip osteoarthritis: a scoping review. BMC Musculoskelet Disord. 2018; 19(1):271. Epub 2018/07/30. https://doi.org/10.1186/s12891-018-2175-7 PMID: 30055599

30. Papalia R, Rampogna B, Torre G, Lanotte A, Vasta S, Albo E, et al. Sarcopenia and its relationship with osteoarthritis: risk factor or direct consequence? Musculoskelet Surg. 2014; 98(1):9–14. Epub 2014/02/01. https://doi.org/10.1007/s12306-014-0311-6 PMID: 24482109

31. Lee SY, Ro HJ, Chung SG, Kang SH, Seo KM, Kim DK. Low Skeletal Muscle Mass in the Lower Limbs Is Independently Associated to Knee Osteoarthritis. PLoS One. 2016; 11(11):e0166385. https://doi.org/10.1371/journal.pone.0166385 PMID: 27832208

32. Kim HT, Kim HJ, Ahn HY, Hong YH. An analysis of age-related loss of skeletal muscle mass and its significance on osteoarthritis in a Korean population. Korean J Intern Med. 2016; 31(3):585–93. Epub 2016/03/16. https://doi.org/10.3904/kjim.2015.156 PMID: 26976151

33. Jeon H, Lee SJ, Lim JY, Chung SG, Lee SJ, Lee SY. Low skeletal muscle mass and radiographic osteoarthritis in knee, hip, and lumbar spine: a cross-sectional study. Aging Clin Exp Res. 2019; 31 (11):1557–62. Epub 2019/01/09. https://doi.org/10.1007/s40520-018-1108-5 PMID: 30617856

34. Kemmner W, Teschler M, Goisser S, Bebenek M, von Stengel S, Bollheimer LC, et al. Prevalence of sarcopenia in Germany and the corresponding effect of osteoarthritis in females 70 years and older living in the community: results of the FORMoSA study. Clin Interv Aging. 2015; 10:1565–73. Epub 2015/10/23. https://doi.org/10.2147/CGA.S89585 PMID: 26491272

35. Lee S, Kim TN, Kim SH. Sarcopenic obesity is more closely associated with knee osteoarthritis than non-sarcopenic obesity: a cross-sectional study. Arthritis Rheum. 2012; 64(12):3947–54. Epub 2012/11/30. https://doi.org/10.1002/art.37696 PMID: 23192792

36. Misra D, Fielding RA, Felson DT, Niu J, Brown C, Nevitt M, et al. Risk of Knee Osteoarthritis With Obesity, Sarcopenic Obesity, and Sarcopenia. Arthritis Rheumatol. 2019; 71(2):232–7. https://doi.org/10.1002/art.40692 PMID: 30106249

37. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 35(6):g7647. Epub 20150102. https://doi.org/10.1136/bmj.g7647 PMID: 25559885

38. Shamseer L, Moreira JP, nipple D, Carver C, Colquhoun I, Liberati A, et al. Preferred reporting items for systematic review and meta-analysis: PRISMA 2015 statement. BMJ. 2015; 351:4237. Epub 20150219. https://doi.org/10.1136/bmj.v5859 PMID: 25559885

39. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses 2010. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

40. Herzog R, Alvarez-Pasquin MJ, Diaz C, Del Barrio JL, Estrada JM, Gil A. Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health. 2013; 13:154. Epub 20130219. https://doi.org/10.1186/1471-2458-13-154 PMID: 23421987
41. Puthran R, Zhang MW, Tam WW, Ho RC. Prevalence of depression amongst medical students: a meta-analysis. Med Educ. 2016; 50(4):456–68. https://doi.org/10.1111/medu.12962 PMID: 26995484

42. Ho KK, Lau LC, Chau WW, Poon Q, Chung KY, Wong RM. End-stage knee osteoarthritis with and without sarcopenia and the effect of knee arthroplasty—a prospective cohort study. BMC Geriatr. 2021; 21(1):2. Epub 20210104. https://doi.org/10.1186/s12877-020-01929-6 PMID: 33397330

43. Barazzoni R, Bischoff SC, Boirie Y, Busetto L, Cederholm T, Dicker D, et al. Sarcopenic obesity: Time to meet the challenge. Clin Nutr. 2018; 37(6 Pt A):1787–93. https://doi.org/10.1016/j.clnu.2018.04.018 PMID: 29857921

44. Holmberg S, Thelin A, Thelin N. Knee osteoarthritis and body mass index: a population-based case-control study. Scand J Rheumatol. 2005; 34(1):59–64. https://doi.org/10.1080/03009740510017922 PMID: 15903028

45. Go SW, Cha YH, Lee JA, Park HS. Association between Sarcopenia, Bone Density, and Health-Related Quality of Life in Korean Men. Korean J Fam Med. 2013; 34(4):281–8. https://doi.org/10.4082/kjfm.2013.34.4.281 PMID: 23904958

46. Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ, et al. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. Int J Biochem Cell Biol. 2013; 45(10):2288–301. https://doi.org/10.1016/j.biocel.2013.06.024 PMID: 23845738

47. Dickinson JM, Volpi E, Rasmussen BB. Exercise and nutrition to target protein synthesis impairments in aging skeletal muscle. Exerc Sport Sci Rev. 2013; 41(4):216–23. https://doi.org/10.1097/JES.0b013e3182a4e699 PMID: 23873131

48. Batsis JA, Mackenzie TA, Bartels SJ, Sahakyan KR, Somers VK, Lopez-Jimenez F. Diagnostic accuracy of body mass index to identify obesity in older adults: NHANES 1999–2004. Int J Obes (Lond). 2016; 40(5):761–7. https://doi.org/10.1038/ijo.2015.243 PMID: 26620887

49. Atkins JL, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannamethee SG. Sarcopenic obesity and risk of cardiovascular disease and mortality: a population-based cohort study of older men. J Am Geriatr Soc. 2014; 62(2):253–60. https://doi.org/10.1111/jgs.12652 PMID: 24428349